臨床泌尿器科67巻12号

2013年11月発行

綜説

前立腺癌に対する診断と治療戦略

著者： 椎名浩昭¹ 安本博晃¹

所属機関： ¹島根大学医学部泌尿器科学教室

ページ範囲：P.929 - P.942

文献概要

要旨　前立腺癌の特徴はアンドロゲン依存性増殖に集約されるが，最近の医療情勢を取り巻く認識の変化，医療技術の急速な進歩，また分子生物学の飛躍的な発展により，多くの新しい知見が得られ前立腺癌の診断・治療における従来の常識は変遷しつつある。限局性前立腺癌に対するロボット支援腹腔鏡下前立腺全摘が保険収載され，初期の前立腺癌はQOL疾患としても認識される一方で，去勢抵抗性前立腺癌はわれわれ泌尿器科医にとってはやはりchallengingな病態で，このような前立腺癌を取り巻く“環境”の変化を踏まえ，当科での前立腺癌に対する診断と治療戦略の方向性を概説する。

参考文献

1）Huggins C and Hodges CV：Studies on prostatic cancer：I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1：293-297, 1941

2）Moul JW, Wu H, Sun L, et al：Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen：an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 132：213-219, 2002

3）Bubley GJ, Carducci M, Dahut W, et al：Eligibility and response guidelines for Phase Ⅱ clinical trials in androgen-independent prostate cancer：recommendations from the prostate-specific antigen working group. J Clin Oncol 17：3461-3467, 1999

4）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512, 2004

5）Petrylak DP, Tangen CM, Hussain MH, et al：Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351：1513-1520, 2004

6）Sedelaar JP, Vijverberg PL, De Reijke TM, et al：Transrectal ultrasound in the diagnosis of prostate cancer：state of the art and perspectives. Eur Urol 40：275-284, 2001

7）Krouskop TA, Wheeler TM, Kallel F, et al：Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging 20：260-274, 1998

8）Cochlin DL, Ganatra RH and Griffiths DF：Elastography in the detection of prostatic cancer. Clin Radiol 57：1014-1020, 2002

9）Sperandeo G, Sperandeo M, Morcaldi M, et al：Transrectal ultrasonography for the early diagnosis of adenocarcinoma of the prostate：a new maneuver designed to improve the differentiation of malignant and benign lesions. J Urol 169：607-610, 2003

10）Konig K, Scheipers U, Pesavento A, et al：Initial experiences with real-time elastography guided biopsies of the prostate. J Urol 174：115-117, 2005

11）洲村正裕，滋野和志，有地直子，他：前立腺癌検出におけるreal-time tissue elastography（RTE）の役割．西日泌尿72：184-189，2010

12）洲村正裕，小原千明，井上圭太，他：Real-time balloon inflation elastography（RBIE）による前立腺癌検出-前立腺針生検における有用性-西日泌尿73：43-50，2011

13）Inoue S, Shiina H, Hiraoka T, et al：Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures. BJU Int 104：1077-1084, 2009

14）Shiina H, Yasumoto H, Igawa M, et al：Essential effect of radical perineal prostatectomy on longitudinal alteration of QOL in patients with localized prostate cancer. Nihon Rinsho 69（Suppl 5）：615-619, 2011

15）Cantile M, Kisslinger A, Cindolo L, et al：cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers. J Cell Physiol 205：202-210, 2005

16）Petrovics G, Zhang W, Makarem M, et al：Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function：is associated with high-risk prostate cancer patients. Oncogene 23：605-611, 2004

17）Mitsui Y, Shiina H, Hiraki M, et al：Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer：novel predictor of biochemical recurrence after radical surgery. Cancer Epidemiol Biomarkers Prev 21：487-496, 2012

18）Ogishima T, Shiina H, Breault JE, et al：Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 11：1028-1036, 2005

19）Enokida H, Shiina H, Igawa M, et al：CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 64：5956-6962, 2004

20）Sun X, Frierson HF, Chen C, et al：Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 37：407-412, 2005

21）Mueller-Lisse UG, Vigneron DB, Hricak H, et al：Localized prostate cancer：effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging：clinicopathologic case-controlled study. Radiology 221：380-390, 2001

22）Coakley FV, Teh HS, Qayyum A, et al：Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy：preliminary experience. Radiology 233：441-448, 2004

23）Scheilder J, Hricak H, Vigneron DB, et al：Prostate cancer：localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213：473-480, 1999

H MR spectroscopic imaging-initial results. Radiology 229：241-247, 2003

25）洲村正裕，有地直子，三井要造，他：内分泌抵抗性前立腺癌におけるDEC療法の局所治療効果―Magnetic resonance spestroscopic image（MRS）による評価―．西日泌尿72：392-398，2010

26）Thurairaja R, McFarlane J, Traill Z, et al：State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 94：268-271, 2004

27）Scher H：Prostate carcinoma：defining therapeutic objectives and improving overall outcomes. Cancer Suppl 97：758-771, 2003

28）Imbriaco M, Larson SM, Yeung HW, et al：A new parameter for measuring metastatic bone involvement by prostate cancer：the bone scan index. Clin Cancer Res 4：1765-1772, 1998

29）Sabbatini P, Larson SM, Kremer A：Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17：948-957, 1999

30）Mitsui Y, Shiina H, Yamamoto Y, et al：Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110（11 PtB）：E628-634, 2012

31）Shiina H, Igawa M and Ishibe T：Estramustine-binding protein to dihydrotestosterone ratio in human prostatic carcinoma：a new marker for predicting disease progression. Br J Urol 77：96-101, 1996

32）Moriyama-Gonda N, Shiina H, Terashima M, et al：Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer：primary evidence based on methylation analysis of oestrogen receptor-alpha. BJU Int 101：485-491, 2008

33）Mosca A, Berruti A, Russo L, et al：The neuroendocrine phenotype in prostate cancer：basic and clinical aspects. J Endocrinol Invest 28：141-145, 2005

34）Urakami S, Igawa M, Kikuno N, et al：Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168：2444-2450, 2002

35）Urakami S, Yoshino T, Kikuno N, et al：Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer：a pilot study. Urology 65：543-548, 2005

36）Kikuno N, Urakami S, Nakamura S, et al：Phase-Ⅱ study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51：1252-1258, 2007

37）Yoshino T, Shiina H, Urakami S, et al：Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12：6116-6124, 2006

38）Nelson JB：Endothelin receptor antagonists. World J Urol 23：19-27, 2005

39）Dahut WL, Gulley JL, Arlen PM, et al：Randomized phase Ⅱ trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22：2532-2539, 2004

40）Kikuno N, Urakami S, Nakamura S, et al：Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone. Int J Urol 14：82-84, 2007

41）Carrano AC, Eytan E, Hershko A, et al：SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol 1：193-199, 1999

42）Latres E, Chiarle R, Schulman BA, et al：Role of the F-box protein Skp2 in lymphomagenesis. Proc Nat Acad Sci 98：2515-2520, 2001